Prognostic value of SMAD4 in resectable pancreatic cancer

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018; 68: 7–30. SiegelRL MillerKD JemalA Cancer statistics, 2018 CA Cancer J Clin 2018 68 7 30 10.3322/caac.2144229313949 Search in Google Scholar

[2] Herman JM, Swartz MJ, Hsu CC, Winter J, Pawlik TM, Sugar E, Robinson R, Laheru DA, Jaffee E, Hruban RH, et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol. 2008; 26: 3503–3510. HermanJM SwartzMJ HsuCC WinterJ PawlikTM SugarE RobinsonR LaheruDA JaffeeE HrubanRH Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital J Clin Oncol 2008 26 3503 3510 10.1200/JCO.2007.15.8469355869018640931 Search in Google Scholar

[3] Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011; 378: 607–620. VincentA HermanJ SchulickR HrubanRH GogginsM Pancreatic cancer Lancet 2011 378 607 620 10.1016/S0140-6736(10)62307-0306250821620466 Search in Google Scholar

[4] Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010; 304: 1073–1081. NeoptolemosJP StockenDD BassiC GhanehP CunninghamD GoldsteinD PadburyR MooreMJ GallingerS MarietteC Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial JAMA 2010 304 1073 1081 10.1001/jama.2010.127520823433 Search in Google Scholar

[5] Regine WF, Winter KA, Abrams R, Safran H, Hoffman JP, Konski A, Benson AB, Macdonald JS, Rich TA, Willett CG. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol. 2011; 18: 1319–1326. RegineWF WinterKA AbramsR SafranH HoffmanJP KonskiA BensonAB MacdonaldJS RichTA WillettCG Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial Ann Surg Oncol 2011 18 1319 1326 10.1245/s10434-011-1630-6354840821499862 Search in Google Scholar

[6] Saiki Y, Horii A. Molecular pathology of pancreatic cancer. Pathol Int. 2014; 64: 10–19. SaikiY HoriiA Molecular pathology of pancreatic cancer Pathol Int 2014 64 10 19 10.1111/pin.1211424471965 Search in Google Scholar

[7] David CJ, Huang YH, Chen M, Su J, Zou Y, Bardeesy N, Iacobuzio-Donahue CA, Massagué J. TGF-beta tumor suppression through a lethal EMT. Cell. 2016; 164: 1015–1030. DavidCJ HuangYH ChenM SuJ ZouY BardeesyN Iacobuzio-DonahueCA MassaguéJ TGF-beta tumor suppression through a lethal EMT Cell 2016 164 1015 1030 10.1016/j.cell.2016.01.009480134126898331 Search in Google Scholar

[8] Jiang H, He C, Geng S, Sheng H, Shen X, Zhang X, Li H, Zhu S, Chen X, Yang C, Gao HJ. RhoT1 and Smad4 are correlated with lymph node metastasis and overall survival in pancreatic cancer. PLoS One. 2012; 7: e42234. JiangH HeC GengS ShengH ShenX ZhangX LiH ZhuS ChenX YangC GaoHJ RhoT1 and Smad4 are correlated with lymph node metastasis and overall survival in pancreatic cancer PLoS One 2012 7 e42234 10.1371/journal.pone.0042234340915122860091 Search in Google Scholar

[9] Javle M, Li Y, Tan D, Dong X, Chang P, Kar S, Li D. Biomarkers of TGF-beta signaling pathway and prognosis of pancreatic cancer. PLoS One. 2014; 9: e85942. JavleM LiY TanD DongX ChangP KarS LiD Biomarkers of TGF-beta signaling pathway and prognosis of pancreatic cancer PLoS One 2014 9 e85942 10.1371/journal.pone.0085942389641024465802 Search in Google Scholar

[10] Handra-Luca A, Hammel P, Sauvanet A, Ruszniewski P, Couvelard A. Tumoral epithelial and stromal expression of SMAD proteins in pancreatic ductal adenocarcinomas. J Hepatobiliary Pancreat Sci. 2013; 20: 294–302. Handra-LucaA HammelP SauvanetA RuszniewskiP CouvelardA Tumoral epithelial and stromal expression of SMAD proteins in pancreatic ductal adenocarcinomas J Hepatobiliary Pancreat Sci 2013 20 294 302 10.1007/s00534-012-0518-622581056 Search in Google Scholar

[11] Blackford A, Serrano OK, Wolfgang CL, Parmigiani G, Jones S, Zhang X, Parsons DW, Lin JCH, Leary RJ, Eshleman JR, et al. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res. 2009; 15: 4674–4679. BlackfordA SerranoOK WolfgangCL ParmigianiG JonesS ZhangX ParsonsDW LinJCH LearyRJ EshlemanJR SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer Clin Cancer Res 2009 15 4674 4679 10.1158/1078-0432.CCR-09-0227281927419584151 Search in Google Scholar

[12] Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Int J Surg. 2010; 8: 336–341. MoherD LiberatiA TetzlaffJ AltmanDG PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement Int J Surg 2010 8 336 341 10.1016/j.ijsu.2010.02.00720171303 Search in Google Scholar

[13] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25: 603–605. StangA Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses Eur J Epidemiol 2010 25 603 605 10.1007/s10654-010-9491-z20652370 Search in Google Scholar

[14] Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8: 16. TierneyJF StewartLA GhersiD BurdettS SydesMR Practical methods for incorporating summary time-to-event data into meta-analysis Trials 2007 8 16 10.1186/1745-6215-8-16192053417555582 Search in Google Scholar

[15] Oshima M, Okano K, Muraki S, Haba R, Maeba T, Suzuki Y, Yachida S. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer. Ann Surg. 2013; 258: 336–346. OshimaM OkanoK MurakiS HabaR MaebaT SuzukiY YachidaS Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer Ann Surg 2013 258 336 346 10.1097/SLA.0b013e3182827a6523470568 Search in Google Scholar

[16] Yamada S, Fujii T, Shimoyama Y, Kanda M, Nakayama G, Sugimoto H, Koike M, Nomoto S, Fujiwara M, Nakao A, Kodera Y. SMAD4 expression predicts local spread and treatment failure in resected pancreatic cancer. Pancreas. 2015; 44: 660–664. YamadaS FujiiT ShimoyamaY KandaM NakayamaG SugimotoH KoikeM NomotoS FujiwaraM NakaoA KoderaY SMAD4 expression predicts local spread and treatment failure in resected pancreatic cancer Pancreas 2015 44 660 664 10.1097/MPA.000000000000031525760429 Search in Google Scholar

[17] Herman JM, Jabbour SK, Lin SH, Deek MP, Hsu CC, Fishman EK, Kim S, Cameron JL, Chekmareva M, Laheru DA, et al. Smad4 loss correlates with higher rates of local and distant failure in pancreatic adenocarcinoma patients receiving adjuvant chemoradiation. Pancreas. 2018; 47: 208–212. HermanJM JabbourSK LinSH DeekMP HsuCC FishmanEK KimS CameronJL ChekmarevaM LaheruDA Smad4 loss correlates with higher rates of local and distant failure in pancreatic adenocarcinoma patients receiving adjuvant chemoradiation Pancreas 2018 47 208 212 10.1097/MPA.0000000000000985580052329329157 Search in Google Scholar

[18] Tascilar M, Skinner HG, Rosty C, Sohn T, Wilentz RE, Offerhaus GJ, Adsay V, Abrams RA, Cameron JL, Kern SE, et al. The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res. 2001; 7: 4115–4121. TascilarM SkinnerHG RostyC SohnT WilentzRE OfferhausGJ AdsayV AbramsRA CameronJL KernSE The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma Clin Cancer Res 2001 7 4115 4121 Search in Google Scholar

[19] Biankin AV, Morey AL, Lee CS, Kench JG, Biankin SA, Hook HC, Head DR, Hugh TB, Sutherland RL, Henshall SM. DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma. J Clin Oncol. 2002; 20: 4531–4542. BiankinAV MoreyAL LeeCS KenchJG BiankinSA HookHC HeadDR HughTB SutherlandRL HenshallSM DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma J Clin Oncol 2002 20 4531 4542 10.1200/JCO.2002.12.06312454109 Search in Google Scholar

[20] Xu JZ, Wang WQ, Zhang WH, Xu HX, Gao HL, Zhang SR, Wu CT, Li S, Li H, Xu J, et al. The loss of SMAD4/DPC4 expression associated with a strongly activated hedgehog signaling pathway predicts poor prognosis in resected pancreatic cancer. J Cancer. 2019; 10: 4123–4131. XuJZ WangWQ ZhangWH XuHX GaoHL ZhangSR WuCT LiS LiH XuJ The loss of SMAD4/DPC4 expression associated with a strongly activated hedgehog signaling pathway predicts poor prognosis in resected pancreatic cancer J Cancer 2019 10 4123 4131 10.7150/jca.30883669262631417657 Search in Google Scholar

[21] Ottenhof NA, Morsink FH, Ten Kate F, van Noorden CJ, Offerhaus GJ. Multivariate analysis of immunohistochemical evaluation of protein expression in pancreatic ductal adenocarcinoma reveals prognostic significance for persistent Smad4 expression only. Cell Oncol (Dordr). 2012; 35: 119–126. OttenhofNA MorsinkFH Ten KateF van NoordenCJ OfferhausGJ Multivariate analysis of immunohistochemical evaluation of protein expression in pancreatic ductal adenocarcinoma reveals prognostic significance for persistent Smad4 expression only Cell Oncol (Dordr) 2012 35 119 126 10.1007/s13402-012-0072-x330656922351431 Search in Google Scholar

[22] Shen J, Gao SZ, Wang H, Shi XH, Li B, Pan YQ, Shen S, Shao Z, Guo SW, Jin G. Prognostic value of important driver gene mutations in patients with radical resection of pancreatic cancer. Zhonghua Wai Ke Za Zhi. 2019; 57: 840–847. ShenJ GaoSZ WangH ShiXH LiB PanYQ ShenS ShaoZ GuoSW JinG Prognostic value of important driver gene mutations in patients with radical resection of pancreatic cancer Zhonghua Wai Ke Za Zhi 2019 57 840 847 Search in Google Scholar

[23] Toga T, Nio Y, Hashimoto K, Higami T, Maruyama R. The dissociated expression of protein and messenger RNA of DPC4 in human invasive ductal carcinoma of the pancreas and their implication for patient outcome. Anticancer Res. 2004; 24: 1173–1178. TogaT NioY HashimotoK HigamiT MaruyamaR The dissociated expression of protein and messenger RNA of DPC4 in human invasive ductal carcinoma of the pancreas and their implication for patient outcome Anticancer Res 2004 24 1173 1178 Search in Google Scholar

[24] Bachet JB, Maréchal R, Demetter P, Bonnetain F, Couvelard A, Svrcek M, Bardier-Dupas A, Hammel P, Sauvanet A, Louvet C, et al. Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma. Ann Oncol. 2012; 23: 2327–2335. BachetJB MaréchalR DemetterP BonnetainF CouvelardA SvrcekM Bardier-DupasA HammelP SauvanetA LouvetC Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma Ann Oncol 2012 23 2327 2335 10.1093/annonc/mdr61722377565 Search in Google Scholar

[25] Winter JM, Tang LH, Klimstra DS, Liu W, Linkov I, Brennan MF, D’Angelica MI, DeMatteo RP, Fong Y, Jarnagin WR, et al. Failure patterns in resected pancreas adenocarcinoma: lack of predicted benefit to SMAD4 expression. Ann Surg. 2013; 258: 331–335. WinterJM TangLH KlimstraDS LiuW LinkovI BrennanMF D’AngelicaMI DeMatteoRP FongY JarnaginWR Failure patterns in resected pancreas adenocarcinoma: lack of predicted benefit to SMAD4 expression Ann Surg 2013 258 331 335 10.1097/SLA.0b013e31827fe9ce443170023360922 Search in Google Scholar

[26] Shin SH, Kim HJ, Hwang DW, Lee JH, Song KB, Jun E, Shim IK, Hong SM, Kim HJ, Park KM, et al. The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: A prospective cohort study. Oncotarget. 2017; 8: 17945–17959. ShinSH KimHJ HwangDW LeeJH SongKB JunE ShimIK HongSM KimHJ ParkKM The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: A prospective cohort study Oncotarget 2017 8 17945 17959 10.18632/oncotarget.14901539229928160547 Search in Google Scholar

[27] Singh P, Srinivasan R, Wig JD. SMAD4 genetic alterations predict a worse prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas. 2012; 41: 541–546. SinghP SrinivasanR WigJD SMAD4 genetic alterations predict a worse prognosis in patients with pancreatic ductal adenocarcinoma Pancreas 2012 41 541 546 10.1097/MPA.0b013e318247d6af22504380 Search in Google Scholar

[28] Hua Z, Zhang YC, Hu XM, Jia ZG. Loss of DPC4 expression and its correlation with clinicopathological parameters in pancreatic carcinoma. World J Gastroenterol. 2003; 9: 2764–2767. HuaZ ZhangYC HuXM JiaZG Loss of DPC4 expression and its correlation with clinicopathological parameters in pancreatic carcinoma World J Gastroenterol 2003 9 2764 2767 10.3748/wjg.v9.i12.2764461204814669329 Search in Google Scholar

[29] Khorana AA, Hu YC, Ryan CK, Komorowski RA, Hostetter G, Ahrendt SA. Vascular endothelial growth factor and DPC4 predict adjuvant therapy outcomes in resected pancreatic cancer. J Gastrointest Surg. 2005; 9: 903–911. KhoranaAA HuYC RyanCK KomorowskiRA HostetterG AhrendtSA Vascular endothelial growth factor and DPC4 predict adjuvant therapy outcomes in resected pancreatic cancer J Gastrointest Surg 2005 9 903 911 10.1016/j.gassur.2005.06.02116137582 Search in Google Scholar

[30] Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, Vilardell F, Wang Z, Keller JW, Banerjee P, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009; 27: 1806–1813. Iacobuzio-DonahueCA FuB YachidaS LuoM AbeH HendersonCM VilardellF WangZ KellerJW BanerjeeP DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer J Clin Oncol 2009 27 1806 1813 10.1200/JCO.2008.17.7188266870619273710 Search in Google Scholar

[31] Crane CH, Varadhachary GR, Yordy JS, Staerkel GA, Javle MM, Safran H, Haque W, Hobbs BD, Krishnan S, Fleming JB, et al. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4 (Dpc4) immunostaining with pattern of disease progression. J Clin Oncol. 2011; 29: 3037–3043. CraneCH VaradhacharyGR YordyJS StaerkelGA JavleMM SafranH HaqueW HobbsBD KrishnanS FlemingJB Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4 (Dpc4) immunostaining with pattern of disease progression J Clin Oncol 2011 29 3037 3043 10.1200/JCO.2010.33.8038315796521709185 Search in Google Scholar

[32] Boone BA, Sabbaghian S, Zenati M, Marsh JW, Moser AJ, Zureikat AH, Singhi AD, Zeh HJ 3rd, Krasinskas AM. Loss of SMAD4 staining in pre-operative cell blocks is associated with distant metastases following pancreaticoduodenectomy with venous resection for pancreatic cancer. J Surg Oncol. 2014; 110: 171–175. BooneBA SabbaghianS ZenatiM MarshJW MoserAJ ZureikatAH SinghiAD ZehHJ3rd KrasinskasAM Loss of SMAD4 staining in pre-operative cell blocks is associated with distant metastases following pancreaticoduodenectomy with venous resection for pancreatic cancer J Surg Oncol 2014 110 171 175 10.1002/jso.2360624665063 Search in Google Scholar

[33] Tanaka T, Watanabe T, Kazama Y, Tanaka J, Kanazawa T, Kazama S, Nagawa H. Chromosome 18q deletion and Smad4 protein inactivation correlate with liver metastasis: a study matched for T- and N-classification. Br J Cancer. 2006; 95: 1562–1567. TanakaT WatanabeT KazamaY TanakaJ KanazawaT KazamaS NagawaH Chromosome 18q deletion and Smad4 protein inactivation correlate with liver metastasis: a study matched for T- and N-classification Br J Cancer 2006 95 1562 1567 10.1038/sj.bjc.6603460236073617088901 Search in Google Scholar

[34] Kang YK, Kim WH, Jang JJ. Expression of G1-S modulators (p53, p16, p27, cyclin D1, Rb) and Smad4/Dpc4 in intrahepatic cholangiocarcinoma. Hum Pathol. 2002; 33: 877–883. KangYK KimWH JangJJ Expression of G1-S modulators (p53, p16, p27, cyclin D1, Rb) and Smad4/Dpc4 in intrahepatic cholangiocarcinoma Hum Pathol 2002 33 877 883 10.1053/hupa.2002.12744412378511 Search in Google Scholar

[35] Zhang B, Halder SK, Kashikar ND, Cho YJ, Datta A, Gorden DL, Datta PK. Antimetastatic role of Smad4 signaling in colorectal cancer. Gastroenterology. 2010; 138: 969–980.e1–3. ZhangB HalderSK KashikarND ChoYJ DattaA GordenDL DattaPK Antimetastatic role of Smad4 signaling in colorectal cancer Gastroenterology 2010 138 969 980.e1–3 10.1053/j.gastro.2009.11.004283110319909744 Search in Google Scholar

[36] Maitra A, Molberg K, Albores-Saavedra J, Lindberg G. Loss of Dpc4 expression in colonic adenocarcinomas correlates with the presence of metastatic disease. Am J Pathol. 2000; 157: 1105–1111. MaitraA MolbergK Albores-SaavedraJ LindbergG Loss of Dpc4 expression in colonic adenocarcinomas correlates with the presence of metastatic disease Am J Pathol 2000 157 1105 1111 10.1016/S0002-9440(10)64625-1185016911021814 Search in Google Scholar

[37] Sun GL, Li Z, Wang WZ, Chen Z, Zhang L, Li Q, Wei S, Li BW, Xu JH, Chen L, et al. miR-324-3p promotes gastric cancer development by activating Smad4-mediated Wnt/beta-catenin signaling pathway. J Gastroenterol. 2018; 53: 725–739. SunGL LiZ WangWZ ChenZ ZhangL LiQ WeiS LiBW XuJH ChenL miR-324-3p promotes gastric cancer development by activating Smad4-mediated Wnt/beta-catenin signaling pathway J Gastroenterol 2018 53 725 739 10.1007/s00535-017-1408-0597104129103082 Search in Google Scholar

[38] Wilentz RE, Iacobuzio-Donahue CA, Argani P. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res. 2000; 60: 2002–2006. WilentzRE Iacobuzio-DonahueCA ArganiP Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression Cancer Res 2000 60 2002 2006 Search in Google Scholar

[39] Zavadil J, Böttinger EP. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene. 2005; 24: 5764–5774. ZavadilJ BöttingerEP TGF-beta and epithelial-to-mesenchymal transitions Oncogene 2005 24 5764 5774 10.1038/sj.onc.120892716123809 Search in Google Scholar

[40] Deckers M, van Dinther M, Buijs J, Que I, Löwik C, van der Pluijm G, ten Dijke P. The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res. 2006; 66: 2202–2209. DeckersM van DintherM BuijsJ QueI LöwikC van der PluijmG ten DijkeP The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells Cancer Res 2006 66 2202 2209 10.1158/0008-5472.CAN-05-356016489022 Search in Google Scholar